← All trials
NCT04949633
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2021
- Primary completion
- Sep 30, 2025
- Completion date
- Nov 30, 2025
- First posted
- Jul 2, 2021
- Last posted
- Oct 18, 2021
- Enrollment
- 1494
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University Hospital, ToursLead sponsor
- University Hospital, ToursStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.